Seyed Amir Raoufi: The Growing Role of CAC and Lp(a) in Preventive Cardiology
Seyed Amir Raoufi, Interventional Cardiologist, shared a post on LinkedIn:
“1. Patient Profile
Age/Gender: middle age Male/Female.
Comorbidities: Controlled Hypertension (on medication), Non-Diabetic.
Clinical Status: Entirely asymptomatic.
Initial Lab Findings: Mildly elevated LDL-C; otherwise normal metabolic profile.
2. Diagnostic Work-up (Guideline 2026 Approach)
To determine the necessity of Antiplatelet and Statin therapy, the following ‘Gatekeeper’ tests are prioritized:
- Lipoprotein(a) [Lp(a)] Measurement: To assess genetic pro-thrombotic and pro-inflammatory risk.
- Coronary Artery Calcium (CAC) Score: To quantify subclinical atherosclerotic burden (The ‘Power of Zero’ versus Plaque Presence).
3. Management Stratification
Scenario A: Low Genomic and Anatomic Risk
- Criteria: Lp(a) less than 50 mg/dL AND CAC equals 0.
- Antiplatelet: ASA Not Indicated.
- Lipid Management: Statin therapy is optional or conservative. LDL-C Target: less than 100 mg/dL (2.6 mmol/L).
Scenario B: Moderate Anatomic Risk
- Criteria: CAC score 1 – 99.
- Antiplatelet: ASA usually withheld unless other high-risk features are present.
- Lipid Management: Initiate Statin. LDL-C Target: less than 70 mg/dL (1.8 mmol/L).
Scenario C: High Genomic or Anatomic Risk
- Criteria: Lp(a) more than 50 mg/dL OR CAC \ge 100.
- Antiplatelet: Initiate Aspirin (81-100 mg) to mitigate the synergistic risk of thrombosis and plaque rupture (Class IIa).
- Lipid Management: High-intensity Statin. LDL-C Target: less than 55 mg/dL (1.4 mmol/L).
4. Clinical Reasoning (Key Takeaways)
The Synergistic Effect: Elevated Lp(a) acts as a pro-thrombotic modifier.
When Lp(a) is high, even non-obstructive plaques (confirmed by CAC more than 0) are more likely to cause an acute event due to impaired fibrinolysis.
Bleeding versus Ischemic Risk: In primary prevention, Aspirin is reserved for patients where CAC \ge 100 or elevated Lp(a) tips the balance in favor of ischemic protection over the risk of GI bleeding.
2026 Shift: We treat the Plaque Biology and Genetic Predisposition rather than just the LDL-C number.
Clinical Pearl: In 2026, the CAC score is no longer just “nice to have”; it is the decisive tool for preventing over-treatment with Aspirin in low-risk individuals and ensuring aggressive protection for those with subclinical disease.”
Stay updated with Hemostasis Today.
-
May 11, 2026, 13:27Milano 2022: Where My Journey Began – Sergio Emanuel Kaiser
-
May 11, 2026, 13:15Vitor Ferreira: VeinPlanner Makes Complex Venous Planning More Efficient
-
May 11, 2026, 13:14Translating Bleeding Risk Models Into Everyday Practice – Thrombosis Canada
-
May 11, 2026, 12:59Munira Borhany: Latest Advances in JAK Inhibitors for Myelofibrosis
-
May 11, 2026, 12:53Muhammet Özbilen: Is the IV Iron Given to Hospitalized Patients Sufficient?
-
May 11, 2026, 12:52Ryan Rodarmer: Writing Through Aortic Disease and Medical Trauma
-
May 11, 2026, 12:51Megan Adediran: The Power of Global Collaboration in Hemophilia Care
-
May 11, 2026, 11:59Polycythemia Vera and Thrombosis: Pathogenesis and Prevention
-
May 11, 2026, 01:38Heghine Khachatryan: The Emerging Era of Immunothrombosis and Precision Vascular Medicine